Patent application for HIV vaccine

Immune response visualised with bioluminescence

A DNA-based vaccine for HIV and Hepatitis C is the subject of a new patent application by University of Adelaide (UoA) researcher, Prof. Eric Gowans. His new system causes a small amount of tissue inflammation at the injection site, which stimulates antigen presenting cells (dendritic cells) in the skin to become active. This generates an immune response robust enough for the vaccination to be successful.

The research team used live-animal imaging in the AMMRF at UoA to track cells specifically labelled with a luminescent dye. This enabled visualisation of the cellular processes, which in turn, allowed optimisation of the vaccine system for maximal immunity. The vaccine is delivered directly to the skin by using a specialised needle that penetrates just 1.5 mm below the surface where there is a high concentration of dendritic cells.

“There’s been a lot of work done in the past to target the dendritic cells, but this has never been effective until now,? Prof. Gowans said.

The research has reached the pre-clinical phase, with a patient study due next year. Prof. Gowans is now in discussions with various companies to find the right commercial partner to help take the project to the next stage.

Related Stories

Hazer Group live on ASX

Hazer Group was established in 2010 from technology developed at UWA to produce clean hydrogen and ...Read More

burn victim

Fast-tracking elastin to market

Prof. Tony Weiss from the University of Sydney in conjunction with Elastagen Pty Ltd has been ...Read More


Nanopatch to tackle polio

The World Health Organization (WHO) is to provide funding to spin-out company, Vaxxas, so it can ...Read More